Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients

Int J Chron Obstruct Pulmon Dis. 2013:8:569-79. doi: 10.2147/COPD.S49307. Epub 2013 Nov 22.

Abstract

Background: Previous studies have demonstrated the potential beneficial effect of N-acetylcysteine (NAC) in chronic obstructive pulmonary disease (COPD). However, the required dose and responder phenotype remain unclear. The current study investigated the effect of high-dose NAC on airway geometry, inflammation, and oxidative stress in COPD patients. Novel functional respiratory imaging methods combining multislice computed tomography images and computer-based flow simulations were used with high sensitivity for detecting changes induced by the therapy.

Methods: Twelve patients with Global Initiative for Chronic Obstructive Lung Disease stage II COPD were randomized to receive NAC 1800 mg or placebo daily for 3 months and were then crossed over to the alternative treatment for a further 3 months.

Results: Significant correlations were found between image-based resistance values and glutathione levels after treatment with NAC (P = 0.011) and glutathione peroxidase at baseline (P = 0.036). Image-based resistance values appeared to be a good predictor for glutathione peroxidase levels after NAC (P = 0.02), changes in glutathione peroxidase levels (P = 0.035), and reduction in lobar functional residual capacity levels (P = 0.00084). In the limited set of responders to NAC therapy, the changes in airway resistance were in the same order as changes induced by budesonide/formoterol.

Conclusion: A combination of glutathione, glutathione peroxidase, and imaging parameters could potentially be used to phenotype COPD patients who would benefit from addition of NAC to their current therapy. The findings of this small pilot study need to be confirmed in a larger pivotal trial.

Trial registration: ClinicalTrials.gov NCT00969904.

Keywords: N-acetylcysteine; chronic obstructive pulmonary disease; computational fluid dynamics; computed tomography; functional respiratory imaging.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / therapeutic use*
  • Aged
  • Airway Resistance / drug effects*
  • Antioxidants / therapeutic use*
  • Computer Simulation
  • Cross-Over Studies
  • Female
  • Forced Expiratory Volume
  • Functional Residual Capacity
  • Glutathione / metabolism
  • Glutathione Peroxidase / metabolism
  • Humans
  • Lung / drug effects*
  • Lung / immunology
  • Lung / metabolism
  • Lung / physiopathology
  • Male
  • Middle Aged
  • Models, Biological
  • Multidetector Computed Tomography
  • Oxidative Stress / drug effects*
  • Phenotype
  • Pilot Projects
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / immunology
  • Pulmonary Disease, Chronic Obstructive / metabolism
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Time Factors
  • Treatment Outcome

Substances

  • Antioxidants
  • Glutathione Peroxidase
  • Glutathione
  • Acetylcysteine

Associated data

  • ClinicalTrials.gov/NCT00969904